MDElliottMD: home-claude category backfill (parser-claude gap closure)

2026-05-23T10:43:44Z

home-claude category backfill (parser-claude gap closure)

← Older revision		Revision as of 10:43, 23 May 2026
Line 21:		Line 21:
	== References ==		== References ==
	<references />		<references />
			[[Category:Progestins]]
			[[Category:Hormonal contraceptives]]
			[[Category:Sex hormones]]

MDElliottMD: parser-claude batch MedTemplate pre-fill, Top 300 #136

2026-05-23T04:19:17Z

parser-claude batch MedTemplate pre-fill, Top 300 #136

New page

{{MedTemplate
| generic = Norethindrone (norethisterone outside US)
| brand = Aygestin (5 mg, Rx); Camila, Errin, Heather, Jolivette, Nor-QD, Ortho Micronor, Sharobel (0.35 mg POPs); component of many COCs
| structure =
| classes = [[:Category:Progestins|Progestin (synthetic progestogen)]], [[:Category:Hormonal_contraceptives|Hormonal contraceptive]], [[:Category:Sex_hormones|Sex hormone]]
| uses = <vote slug="contraception-pop-use">Progestin-only oral contraception</vote>, <vote slug="amenorrhea-use">Secondary amenorrhea</vote>, <vote slug="endometriosis-use">Endometriosis</vote>, <vote slug="dub-use">Dysfunctional uterine bleeding</vote>, <vote slug="hrt-endometrial-protection-use">Endometrial protection in estrogen-containing HRT</vote>
| starting_dose = POP: 0.35 mg PO daily continuously (no placebo week); high-dose 5 mg Aygestin for amenorrhea/endometriosis 5-10 mg/d
| preparations = 0.35 mg POP tablets; 5 mg tablets (Aygestin); component of COCs and combination HRT
| fda_max = Indication-specific
| pill_id =
| routes = Oral
| onset = Contraception within 48 hours of starting (POP); endometrial effects days
| duration = ~24 hours per dose (strict timing required for POP — within 3-hour window each day)
| halflife = ~8 hours<ref name="micronor-label">FDA Prescribing Information, Ortho Micronor (norethindrone), Janssen, current revision. https://www.accessdata.fda.gov/drugsatfda_docs/label/2008/017558s066lbl.pdf</ref>
| bioavailability = ~65% (oral)<ref name="micronor-label" />
| pregnancy = Contraindicated in known pregnancy (Aygestin); the 0.35 mg POP is not teratogenic and does not need to be discontinued before conception planning.{{citation needed}}
| legal = [[USLegal:Prescription only|Rx-only]] in US (note: norgestrel 0.075 mg POP is now OTC as Opill since 2023, but norethindrone POP remains Rx)
| mechanism = <vote slug="norethindrone-mech-claim">Norethindrone is a 19-nortestosterone-derived progestin with progesterone receptor agonism plus weak androgen and estrogen receptor activity; the contraceptive effect comes primarily from cervical mucus thickening (the dominant POP mechanism at 0.35 mg, since ovulation suppression is incomplete) plus endometrial decidualization.</vote> Higher-dose Aygestin (5 mg) achieves more reliable ovulation suppression and is used for endometriosis and DUB. POP requires strict daily timing because the 24-hour cervical-mucus effect window is narrower than COC<ref name="micronor-label" />.
}}

== References ==
<references />

Norethindrone - Revision history

MDElliottMD: home-claude category backfill (parser-claude gap closure)

MDElliottMD: parser-claude batch MedTemplate pre-fill, Top 300 #136